Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma

References

• Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 2002; 30: 813–831
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch D C, Dreger P, Goldstone A H, Boogaerts M A, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Nademanee A, Sniecinski I, Schmidt G M, Dagis A C, O'Donnell M R, Snyder D S, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176–2186
   PubMed Web of Science ®Google Scholar
• Kamel A M, El-Sharkawy N, Mahmoud H K, Khalaf M R, El Haddad A, Fahmy O, et al. Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 129–136
   PubMed Web of Science ®Google Scholar
• Shepherd K M, Charles P, Sage R E, Dale B M, Norman J E, Kotasek D, et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25–32
   PubMedGoogle Scholar
• Tarella C, Ferrero D, Bregni M, Siena S, Gallo E, Pileri A, et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J cancer 1991; 27: 22–27
   PubMed Web of Science ®Google Scholar
• Craig J I, Anthony R S, Stewart A, Thomson E B, Gillon J, Parker A C. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 1993; 85: 210–212
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290
   PubMed Web of Science ®Google Scholar
• Lerro K A, Medoff E, Wu Y, Seropian S E, Snyder E, Krause D, et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 2003; 32: 113–117
   Web of Science ®Google Scholar
• Olivieri A, Offidani M, Ciniero L, Cantori I, Ombrosi L, Mancini S, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16: 85–93
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Territo M, Andrey J, Mason J. A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant. J Hematother Stem Cell Res 2001; 10: 887–893
   PubMedGoogle Scholar
• Clark A D, Douglas K W, Mitchell L D, McQuaker I G, Parker A N, Tansey P J, et al. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br H Haematol 2002; 117: 605–612
   PubMed Web of Science ®Google Scholar
• Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005; 46: 1017–1022
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Truemper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Salles G, Foussard C, Mounier N, Morschhauser F, Doyen C, Lamy T, et al. Rituximab added to αIFN + CHVP improves the outcome of folicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 2004; 104, abstr 160
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593
   PubMed Web of Science ®Google Scholar
• Joyce R M, Kraser C N, Tetrealt J C, Giallombardo N, McDermott D, Levine J, et al. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME;with neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol 2001; 66(Suppl. 64)56–62
   Google Scholar
• Emmanouilides C, Lill M, Telatar M, Rosenfelt F, Grody W, Territo M, et al. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. Clin Lymphoma 2002; 3: 111–116
   PubMedGoogle Scholar
• Bieker R, Kessler T, Berdel W E, Mesters R M. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep 2003; 10: 1915–1917
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diébold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Oken M M, Creech R H, Tormay D C, Horton J, Davis T E, McFadden E T, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning J S, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life tables. J Roy Stat Soc 1972; 34: 187–220
   Google Scholar
• Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869
   PubMed Web of Science ®Google Scholar
• Benekli M, Hahn T, Shafi F, Qureshi A, Alam A R, Czuczman M S, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139–143
   PubMed Web of Science ®Google Scholar
• Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 703–707
   PubMed Web of Science ®Google Scholar
• Hoerr A L, Gao F, Hidalgo J, Tiwari D, Blum K A, Mathews V, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–422
   PubMed Web of Science ®Google Scholar
• Kobbe G, Sohngen D, Bauser U, Schneider P, Germing U, Thiele K P, et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999; 78: 456–462
   PubMed Web of Science ®Google Scholar
• Haas R, Moos M, Karcher A, Mohle R, Witt B, Goldschmidt H, et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685–1692
   PubMed Web of Science ®Google Scholar
• Perea G, Sureda A, Martino R, Altes A, Martinez C, Cabezudo E, et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592–597
   PubMed Web of Science ®Google Scholar
• Gordan L N, Sugrue M W, Lynch J W, Williams K D, Khan S A, Wingard J R, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815–820
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Nousiainen T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?. Bone Marrow Transplant 2003; 32: 569–573
   PubMed Web of Science ®Google Scholar
• Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson J B, Nanji S, et al. Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 5(Suppl 14)115–122
   Google Scholar
• Flinn I W, O'Donnell P V, Goodrich A, Vogelsang G, Abrams R, Noga S, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632
   PubMed Web of Science ®Google Scholar
• Voso M T, Pantel G, Weis M, Schmidt P, Martin S, Moos M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729–735
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Mounier N. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. Semin Oncol 2003; 30(Suppl 2)28–33
   PubMed Web of Science ®Google Scholar
• Hertzberg M S, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock K F. Outpatient-based ifosfamide, carboplatin and etoposide (ICE;chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol 2003; 14(Suppl 1)i11–16
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar